CRNX
Crinetics Pharmaceuticals, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -8.3% ·
share flow +19.5% ·
net new positions -9.1%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | -2 | 71.69M | $2.68B | +4 | −7 |
| Q1 2026 | 93 | +2 | 73.05M | $2.65B | +9 | −7 |
| Q4 2025 | 90 | 0 | 75.54M | $3.52B | — | — |
| Q3 2025 | 15 | 0 | 56.94M | $2.37B | — | — |
| Q2 2025 | 12 | 0 | 51.44M | $1.48B | +1 | −1 |
| Q1 2025 | 9 | -2 | 19.08M | $640.10M | +2 | −4 |
| Q4 2024 | 11 | -1 | 21.01M | $1.07B | — | −1 |
| Q3 2024 | 11 | -2 | 14.60M | $745.98M | — | −2 |
| Q2 2024 | 13 | — | 14.80M | $663.11M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 6.95M | +55.9% | $355.38M | 0.1% | ▲ Add | 3 | SEC ↗ ×8 |
| 2 | T. Rowe Price ✦ | 5.41M | +9.5% | $276.84M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passive) | 2.99M | — | $152.92M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Point72 Asset Management ✦ | 2.79M | +21.2% | $142.60M | 0.4% | ▲ Add | 3 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 2.10M | +13.6% | $107.34M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | Fisher Asset Management ✦ | 559.29K | +16.0% | $28.60M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Duquesne Family Office ✦ | 122.70K | -60.3% | $6.27M | 0.2% | ▼ Trim | 3 | SEC ↗ |
| 8 | Adage Capital Partners ✦ | 65.00K | +62.5% | $3.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | D. E. Shaw & Co. ✦ | 9.88K | -85.0% | $504,960 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 7.80K | +3.0% | $398,712 | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 11 | Citadel Advisors ✦ | 4.72K | -96.5% | $241,436 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Two Sigma Investments | $276,655 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 241 holders, 121.45M shares, $4.08B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.